As our bodies undergo hormonal shifts during perimenopause and beyond, symptoms like hot flashes, sleep troubles and mood swings are expected. But what’s less discussed is the dryness, discomfort and ...

The vagina is the outer portion of the birthing canal that encloses the mouth of the uterus or the cervix. It is lined with mucous membranes and normally the female hormone estrogen helps to keep ...

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...

SMA is a neuromuscular disease that has the following clinical characteristics: Degeneration of lower motor neurons in the spinal cord motor (anterior horn neurons) and the brain nuclei Skeletal ...

Your body—and, specifically, your vagina—goes through changes throughout your life. That's especially true during menopause, when things can start to feel different down there. Menopause causes your ...

Geographic atrophy (GA), the late stage of age-related macular degeneration (AMD), may lead to vision loss. Here’s what to expect as the condition progresses. About 1 million people in the United ...

On Twitter, people are declaring that when this time is over, they are going to hug every human being they see, in long, enfolding hugs, immersing themselves and their recipients in the power of human ...

Please provide your email address to receive an email when new articles are posted on . Multiple system atrophy — whose worldwide awareness day is commemorated every Oct. 3 — includes disorders that ...

Spinal muscular atrophy (SMA) type 1 is a genetic condition in which the nerves that control movement, breathing, and swallowing become progressively weaker and smaller. SMA has five types with ...

On Twitter, people are declaring that when this time is over, they are going to hug every human being they see, in long, enfolding hugs, immersing themselves and their recipients in the power of human ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...